Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets
Date:10/6/2010

COLUMBUS, Ohio, Oct. 6 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg and 100mg as well as Losartan Potassium and Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food and Drug Administration. Both products are available for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Losartan Potassium Tablets USP are AB rated to COZAAR® (losartan potassium) tablets while Losartan Potassium and Hydrochlorothiazide Tablets are AB rated to HYZAAR® (losartan potassium and hydrochlorothiazide) tablets. Annual sales of COZAAR® are approximately $940.2 Million(1) while annual sales of HYZAAR® are approximately $670.7 Million(1).

Full prescribing information for Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 6/2010

COZAAR® and HYZAAR® are registered trademarks of Merck & Co., Inc.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roxane Laboratories, Inc. Announces the Launch of Naratriptan Tablets USP
2. Roxane Laboratories, Inc. Announces the Launch of Anastrozole Tablets
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of Eddie Munson to Board of Directors
5. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
6. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
7. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
10. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Visiomed, the French leader in ... is changing the landscape of healthcare with their ... pro-active, custom-made solutions. Recognizing the rising demand of ... healthcare without walls, Visiomed has launched BewellConnect, the ... healthcare professionals that is empowering the lives of ...
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services ... The announcement was made by Bill Monast , ... Hartley and Nathan Feltman , executives with ... Healthcare Services, LLC. This acquisition helps ... provider of technology enabled durable medical equipment (DME) solutions ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby ... America, today announced it would be offering some it’s exclusive product line to ... crafting quality and unique baby clothing/feeding products, will team up with AMAZON to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in persons with a specific LRRK2 mutation, according to a study released today ... have provided evidence of a link between pesticides and incidence of sporadic PD ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
Breaking Medicine News(10 mins):